Abstract:Breast cancer is a malignant tumor that predominantly affects women. The incidence of breast cancer has risen annually and is increasingly occurring in younger population, posing a significant threat to women’s health. Estrogen receptor-positive breast cancer is the most prevalent subtype, accounting for 75% of all cases. Endocrine therapy, particularly with tamoxifen, serves as the primary treatment for these subtypes. However, due to the highly heterogeneous nature of breast cancer, some patients remain at risk for recurrence even after undergoing tamoxifen treatment. Therefore, it is essential to investigate the mechanism of tamoxifen in breast cancer treatment from a single-cell perspective. In comparison to single-cell genomics and single-cell proteomics, single-cell metabolomics can offer a clearer representation of the chemical changes occurring within individual cells by measuring the end products of cellular activity—metabolites. Thus, this approach can provide a more direct reflection of the differences between cells. In this study, single-cell mass cytometry was employed to investigate metabolite alterations in MCF-7 cells upon exposure to tamoxifen, aiming to elucidate its mechanism from a single-cell perspective. The 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay was utilized to assess the impact of tamoxifen on MCF-7 cell proliferation and established optimal conditions for subsequent therapies involving these cells. The results showed that 576 metabolites under positive ion mode and 480 metabolites under negative ion mode are identified by using single-cell mass cytometry approach. In total, 811 metabolites are detected in MCF-7 cells without tamoxifen treatment compared to 776 metabolites identified following tamoxifen administration. It demonstrated that metabolites observed under negative ion mode effectively distinguish between MCF-7 cells treated with and without tamoxifen. Exposure to tamoxifen can result in upregulation of 28 metabolites and downregulation of 59 metabolites, and these changes predominantly influence metabolic pathways including taurine-hypotaurine metabolism, caffeine metabolism, cysteine-methionine metabolism, glycine-serine-threonine metabolism, purine metabolism, starch-sucrose metabolism, and pyrimidine metabolism. The findings indicated that the intervention of the aforementioned metabolites and metabolic pathways may represent one of the mechanisms through which tamoxifen exerts its effects against estrogen receptor-positive breast cancer. This study employed single-cell metabolomics based on mass spectrometry to explore the metabolic alterations in breast cancer cells induced by tamoxifen, which is often overlooked in metabolomics studies based on bulk cells. Furthermore, it elucidates the mechanism of tamoxifen’s action against estrogen receptor-positive breast cancer from a single-cell metabolomic perspective, thereby provides valuable insights for understanding the mechanisms underlying other therapeutic agents.

Proteomics Analysis of Tamoxifen-induced Autophagic MCF-7 Cells

Study on the Effects of 17Β-Oestradiol and Tamoxifen on the Content of Intracellular Proteins by Itraq Labeling /LC-MALDI-TOF-TOF Analysis

A Proteomic Landscape of Pharmacologic Perturbations for Functional Relevance

Analysis of differentially expressed nuclear matrix proteins of breast cancer and matched normal breast tissues by 2-DE and MALDI-TOF-MS

Transcriptome profiling identified differentially expressed genes and pathways associated with tamoxifen resistance in human breast cancer

Identification of Differentially Expressed Proteins in Colorectal Cancer by Proteomics: Down-regulation of Secretagogin

[Analysis of the Effects of 17Beta-Oestradiol and Serum Deprivation on the Contents of Proteins in Breast Cancer Cells by Isobaric Tags for Relative and Absolute Quantification and Two-Dimensional Liquid Chromatography-Tandem Mass Spectrometry].

Identification of differentially expressed genes in human breast cancer cells induced by 4-hydroxyltamoxifen and elucidation of their pathophysiological relevance and mechanisms

Proteomic Analysis of Differentially Expressed Proteins in 5-Fluorouracil-treated Human Breast Cancer MCF-7 Cells

Proteomic analysis to identify differentially expressed proteins between subjects with metabolic healthy obesity and non-alcoholic fatty liver disease.

Identification of proteins responsible for the multiple drug resistance in 5-fluorouracil-induced breast cancer cell using proteomics analysis

Study on the Mechanism of Tamoxifen Against Breast Cancer by Mass Spectrometry Based Single-Cell Metabolomics

Comparative proteomic study for profiling differentially expressed proteins between Chinese left- and right-sided colon cancers.

Proteomic Identification Of Differentially Expressed Proteins Associated With The Multiple Drug Resistance In Methotrexate-Resistant Human Breast Cancer Cells

Studies on Resistant Induction of Breast Cancer Cell MCF-7 to Tamoxifen in Vitro

A targeted proteomics approach to the quantitative analysis of ERK/Bcl-2-mediated anti-apoptosis and multi-drug resistance in breast cancer

Identification of Breast Cancer Metastasis‐associated Proteins in an Isogenic Tumor Metastasis Model Using Two‐dimensional Gel Electrophoresis and Liquid Chromatography‐ion Trap‐mass Spectrometry

Antigen-subtracted 2-DE/MS strategy, a novel proteomic analysis platform

Comparative Proteomic Analysis of Drug Trichosanthin Addition to BeWo Cell Line

Identification and characterization of critical genes associated with tamoxifen resistance in breast cancer

Analysis of Differential Protein Expression Profile Between Paclitaxel Resistant and Sensitive Lung Adenocarcinoma Cells